08:02 EDT Aurinia to acquire Kezar Life Sciences (KZR) for $6.955 in cash per share plus CVR
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUPH:
- Aurinia to acquire Kezar Life Sciences for $6.955 in cash per share plus CVR
- Aurinia Reshapes C-Suite as Investor Kevin Tang Takes CEO Role Without Pay
- MKT Capital ‘applauds’ Aurinia’s management transition
- Aurinia Reshapes Executive Team as Board Chair Kevin Tang Becomes CEO
- Aurinia Pharmaceuticals announces Tang to succeed Greenleaf as CEO